Effect of evobrutinib, a Bruton's tyrosine kinase inhibitor, on patient-reported vitality and mental health in patients with relapsing multiple sclerosis in a Phase 2 trial

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2023
This article has no abstract
Epistemonikos ID: f12375e1968289486a2dff09ad0710ab5a811060
First added on: Jan 10, 2026